Sanofi's factory of the future named world's best overall facility by International Society for Pharmaceutical Engineering
* Award recognizes innovative accomplishments in facility design, construction, and operation that are setting the standard for pharmaceutical facilities of the future
* One of the first of its kind in the world, the facility is an industry game changer

BRIDGEWATER, N.J., Nov. 3, 2020 /PRNewswire/ -- Sanofi has won the prestigious International Society for Pharmaceutical Engineering (ISPE) Overall Facility of the Year Award for its digitally-enabled continuous biomanufacturing facility located in Framingham, Mass.   This marks the second major award for this facility. In April 2020, Sanofi received the ISPE award in the Factory of the Future category.

The Facility Of the Year Award program showcases accomplishments in facility design, construction, and operation. It celebrates the shared commitment and dedication of individuals working for different companies worldwide to enhance patient health and safety through innovation and advancements in pharmaceutical manufacturing technology.

The Framingham facility, which opened in October 2019, is one of the world's first digital facilities using intensified, continuous biologics production technology. The facility's advanced paperless and data-driven manufacturing technologies enables Sanofi to achieve higher levels of productivity, agility, and flexibility, reducing the time it takes for products to move from the development labs to the manufacturing plant. It recently launched its first commercially approved product in September 2020.

"Winning this award is a tremendous recognition of our ambition to make the factory of the future a reality and to become a world leader in the production of biologic products," said Philippe Luscan, Executive Vice President, Global Industrial Affairs. "What we have achieved at Sanofi Framingham paves the way for the transformation of our entire global industrial network around the world. I am very proud and grateful for the success of our teams."

For more information about the ISPE award, click here. For more information about Sanofi's digitally enabled continuous manufacturing facility click here.

About the ISPE Facility of the Year Awards Program
Established in 2004, The Facility of the Year Awards (FOYA) recognize state-of-the-art projects utilizing new, innovative technologies to improve the quality of products, reduce the cost of producing high-quality medicines, and demonstrate advances in project delivery. The FOYA program provides a platform for the pharmaceutical science and manufacturing industry to showcase its accomplishments in facility design, construction, and operation, while sharing the development of new applications of technology and cutting-edge approaches. Visit ISPE.org/FOYA for more information.

About ISPE
The International Society for Pharmaceutical Engineering (ISPE) is the world's largest not-for-profit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle. The 18,500 members of ISPE are building solutions in the development and manufacture of safe, effective pharmaceutical and biologic medicines, and medical delivery devices in more than 90 countries around the world. Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA. Visit ISPE.org for more information.

About Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

 

Media Relations Contact
Nicolas Kressmann

Tel.: +1 732-532-5318

Nicolas.Kressmann@sanofi.com



Investor Relations Contacts Paris
Eva Schaefer-Jansen
Arnaud Delepine
Yvonne Naughton


Investor Relations Contacts North America
Felix Lauscher
Fara Berkowitz
Suzanne Greco


IR main line:
Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com

 

Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation,  trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole.  Any material effect of COVID-19 on any of the foregoing  could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2019. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

SOURCE Sanofi